Skip to content

US · BIO · MEDICAL - DEVICES

Bio-Rad Laboratories, Inc. (BIO) intrinsic value and stock valuation

$358.90as of 2026-11-21 · Mkt cap 9.36B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bio-Rad Laboratories, Inc. DCF and intrinsic value

InvestorsCraft values BIO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BIO’s statements →

Bio-Rad Laboratories, Inc. Graham Number

Graham Number: $414.07d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Hercules, CA 94547 bio-rad.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.58B+0.3% 5y CAGRd
20112025
Net income
$759.9M-27.6% 5y CAGRd
20112025
Free cash flow
$374.6M-4.7% 5y CAGRd
20112025
Total equity
$7.45B-5.5% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.58B$2.57B$2.67B$2.8B$2.92B
Operating income$270.5M$269M$337.8M$482.6M$500.3M
Net income$759.9M-$-1.84B-$-637.32M-$-3.63B$4.25B
EPSd$27.9M-$-65.37M-$-21.82M-$-121.77M$140.8M
Operating cash flow$532.2M$455.2M$374.9M$194.5M$669.5M
Capital expenditure-$-157.6M-$-189M-$-156.68M-$-114.16M-$-133.75M
Free cash flow$374.6M$266.2M$218.3M$80.3M$535.7M
Total assets$10.6B$9.36B$12.3B$13.5B$17.8B
Total debt$1.53B$1.37B$1.41B$1.39B$223.4M
Net debt$999.2M$886.6M$1B$953.9M-$-247.41M
Total equity$7.45B$6.57B$8.74B$9.62B$13.7B
Cash and short-term investments$1.54B$1.66B$1.61B$1.79B$869.9M
Income statement
20252024202320222021
Revenue$2.58B$2.57B$2.67B$2.8B$2.92B
Cost of revenue$1.24B$1.19B$1.24B$1.23B$1.28B
Gross profit$1.34B$1.38B$1.43B$1.57B$1.64B
Research and development expenses$256.9M$295.9M$247.4M$256.9M$260.6M
Selling, general and administrative expenses$819.9M$814M$841.7M$827.8M$877.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$1.08B$1.11B$1.09B$1.08B$1.14B
Cost and expenses$2.32B$2.3B$2.33B$2.32B$2.42B
Interest income$95.5M$82M$100.9M$58M$18.9M
Interest expense$49M$48.9M$49.4M$38.1M$1.55M
Depreciation and amortization$205.4M$151.6M$145.9M$177.2M$137.6M
Ebitda$1.25B-$-2.14B-$-654.8M-$-4.49B$5.59B
Operating income$270.5M$269M$337.8M$482.6M$500.3M
Total other income/expenses, net$725M-$-2.61B-$-1.19B-$-5.19B$4.95B
Income before tax$995.5M-$-2.34B-$-850.1M-$-4.7B$5.45B
Income tax expense$235.6M-$-498.3M-$-212.78M-$-1.08B$1.19B
Net income$759.9M-$-1.84B-$-637.32M-$-3.63B$4.25B
Weighted average shares outstanding$27.3M$28.2M$29.2M$29.8M$29.8M
Weighted average diluted shares outstanding$27.3M$28.2M$29.2M$29.8M$30.2M
Balance sheet
20252024202320222021
Cash and short-term investments$1.54B$1.66B$1.61B$1.79B$869.9M
Net receivables$472.5M$452.5M$489M$494.6M$423.5M
Inventory$740.7M$760M$780.5M$719.3M$572.2M
Total current assets$2.91B$3.03B$3.05B$3.16B$1.99B
Property, plant and equipment, net$709.9M$688.6M$723.7M$679.6M$716.4M
Goodwill and intangible assets$754.1M$704.1M$734.1M$738.6M$601.2M
Long-term investments$6.1B$4.84B$7.7B$8.83B$14.4B
Total non-current assets$7.67B$6.33B$9.25B$10.3B$15.8B
Total assets$10.6B$9.36B$12.3B$13.5B$17.8B
Accounts payable$129M$122.3M$144.6M$135M$141.9M
Short-term debt$37.9M$42.9M$40.9M$36.8M$36.9M
Deferred revenue$0.00$0.00$0.00$52.2M$50.9M
Total current liabilities$517M$467.8M$522.8M$568.7M$680.9M
Long-term debt$1.49B$1.33B$1.36B$1.35B$186.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.61B$2.33B$3.04B$3.32B$3.43B
Capital lease obligations$154.4M$173.1M$205.9M$189.9M$212.4M
Total liabilities$3.12B$2.79B$3.56B$3.89B$4.11B
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings$8.18B$7.42B$9.26B$9.9B$13.5B
Accumulated other comprehensive income (loss)-$-189.1M-$-538.2M-$-336M-$-466.82M-$-175.55M
Total equity$7.45B$6.57B$8.74B$9.62B$13.7B
Total investments$7.11B$6.02B$8.9B$10.2B$14.8B
Total debt$1.53B$1.37B$1.41B$1.39B$223.4M
Net debt$999.2M$886.6M$1B$953.9M-$-247.41M
Cash flow statement
20252024202320222021
Net income$759.9M-$-1.84B-$-637.3M-$-3.63B$4.25B
Depreciation and amortization$165.4M$151.6M$145.9M$137.3M$137.6M
Stock-based compensation$58M$62.3M$61.3M$60.9M$51.2M
Change in working capital$272.4M-$-620.8M-$-432.8M-$-1.61B$1.14B
Accounts receivable$19.6M$16.2M$11.4M-$-87.4M-$-20.4M
Inventory$68.9M$8.5M-$-46.3M-$-158.8M$46.1M
Accounts payable-$-100K-$-40.9M-$-51.8M-$-94.2M$69.9M
Net cash provided by operating activities$532.2M$455.2M$374.9M$194.5M$669.5M
Investments in property, plant and equipment-$-157.6M-$-165.6M-$-156.68M-$-112.78M-$-133.75M
Acquisitions, net-$-218.4M$0.00$2.5M-$-99.39M-$-125.52M
Net cash used for investing activities-$-189.7M-$-160.2M$20.2M-$-1.21B-$-797.38M
Common stock issued$15.8M$0.00$0.00$0.00$0.00
Common stock repurchased-$-295.5M-$-203.6M-$-428.73M-$-215.68M-$-50M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-283.2M-$-218.8M-$-425.65M$973.6M-$-55.43M
Net change in cash$40.3M$85.4M-$-30.18M-$-36.59M-$-195.98M
Cash at end of period$532.2M$489.8M$404.4M$434.5M$471.1M
Operating cash flow$532.2M$455.2M$374.9M$194.5M$669.5M
Capital expenditure-$-157.6M-$-189M-$-156.68M-$-114.16M-$-133.75M
Free cash flow$374.6M$266.2M$218.3M$80.3M$535.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bio-Rad Laboratories, Inc.

        Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

        CEO
        Norman D. Schwartz
        Employees
        7.45K
        Beta
        1.08

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Bio-Rad Laboratories, Inc. (BIO)?

        Bio-Rad Laboratories, Inc. (BIO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BIO undervalued?

        BIO trades at a price of $358.90 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.